{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-028776","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.585162+00:00","generated_at":"2026-05-24T03:58:57.180934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioXcel Therapeutics Q4 net loss $10.9M; SERENITY Phase 3 trial 63% enrolled; cash ~$35M","bullets":["Net loss $10.9M in Q4 2024 vs $22.3M Q4 2023; full-year net loss $59.6M vs $179.1M.","IGALMI net revenue $366K in Q4 ($376K Q4 2023); full-year $2.3M vs $1.4M in 2023.","SERENITY At-Home Phase 3 trial enrollment at 63% (127/200 patients); topline data expected H2 2025.","Closed $14M equity financing, strengthening cash to ~$35M as of March 4, 2025 (from $29.9M Dec 31, 2024).","Cash used in operating activities $72M in 2024, down from $155M in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-028776","json":"https://secwatch.observer/filing/0001104659-25-028776.json","markdown":"https://secwatch.observer/filing/0001104659-25-028776.md","text":"https://secwatch.observer/filing/0001104659-25-028776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925028776/0001104659-25-028776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925028776/tm2510663d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:58:57.180934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}